DRUG-RESISTANT TUBERCULOSIS (DR-TB) is
now found in all countries where drug susceptibility testing (DST) is available. 1 Of the estimated 440 000 cases of multidrug-resistant TB (MDR-TB) emerging each year, at least 10% are believed to be resistant to additional second-line anti-tuberculosis drugs and can be defi ned as extensively drug-resistant TB (XDR-TB). Treatment outcomes, even under optimal conditions, are relatively poor for MDR-TB compared to drug-susceptible TB, and are substantially poorer for XDR-TB. [2] [3] [4] The World Health Organization (WHO) reports that among 7063 patients from 13 countries who initiated second-line treatment for MDR-TB in 2007, only 37% were successfully treated and 20% either died or failed treatment. 5 Similarly poor outcomes are reported for XDR-TB patients, many of whom were MDR-TB treatment failures. 3, 6 Treatment options for patients in whom second-line treatment for MDR-TB has failed or those who have XDR-TB are extremely limited. Treatment often relies on a set of drugs with poorly established effi cacy and severe adverse event profi les. 7 Poor effi cacy and tolerability leads to treatment discontinuation in many settings, which carries the risk of increased mortality and transmission of highly resistant strains.
Linezolid is an oxazolidinone, a relatively new class of antibiotic primarily used for the treatment of gram-positive bacterial infections. Linezolid has demonstrated high in vitro antibacterial activity against Mycobacterium tuberculosis, 8, 9 and has been used to treat complicated cases of resistant TB in several programmes. [10] [11] [12] Given that patients with refractory and/or XDR-TB have few treatment options, linezolid may well be a useful addition to the armamentarium. However, linezolid is a toxic drug with significant side effects, including severe neuropathies and haematological adverse events. 13 While labelled use of linezolid is restricted to 28 days, with dosage at 600 mg twice daily, DR-TB requires a much longer treatment duration, often for ⩾2 years, and therefore carries an increased likelihood of severe adverse
The International Journal of Tuberculosis and Lung Disease events. The balance between potential effi cacy and drug toxicity has led some to explore a dose reduction for linezolid in the treatment of DR-TB, but experience to date is limited and fragmented. To assess this further, we reviewed the existing evidence of safety and effi cacy of linezolid for the treatment of DR-TB.
METHODS
This systematic review was conducted according to the guidelines for reporting systematic reviews of observational studies by the MOOSE (Meta-analysis of Observational Studies in Epidemiology) group. 14 
Search strategy and selection criteria
We searched PubMed and Embase from January 2000 (when linezolid was fi rst approved for use for indications other than TB) to February 2011 using the key words 'linezolid', 'oxazolidinone' and 'tuberculosis'. We also searched for relevant abstracts of all electronically retrievable abstracts of the World Conferences on Lung Health of The Union (from 2004 to 2010). Reference lists of all retrieved articles and selected review articles were also searched for additional references. All potentially eligible articles were reviewed for inclusion by both authors.
Studies were included if linezolid was used as treatment for MDR-TB and fi nal treatment outcomes were available for at least some of the patients. Case series with ⩽3 cases were excluded to limit potential outcome reporting bias. Studies were excluded if their study population comprised only patients included in a later study, or if authors reported 'substantial overlap' when contacted. No language restrictions were applied.
Data extraction
Data were extracted according to a pre-defi ned extraction form by the fi rst author and verifi ed by the second author. The following data were extracted: fi rst author, publication year, study setting, study design, observation period, number of patients treated, patient inclusion criteria, drug resistance profi le, prior treatment with second-line drugs, description of treatment regimen used in conjunction with linezolid, human immunodefi ciency virus (HIV) status, starting dose of linezolid, duration of linezolid treatment and treatment outcomes. Linezolid dose was recorded as the initial starting dose, except when the regimen specifi ed a higher lead-in dose for a set period of less than one month. Additional data on the description, incidence, timing and outcome of adverse events were also extracted. Where data on linezolid dose, dosing strategy and HIV infection were missing, and in the case of duplicate reports, authors from fi ve studies were contacted to ascertain missing data and the extent of overlap between studies.
We assessed the following factors as determinants of methodological quality: dose of drug reported, use of individualised treatment regimens guided by DST, defi nition of treatment success, availability of higher generation fl uoroquinolones (used for at least one patient), hospitalisation at initiation of linezolid treatment, availability of DST for linezolid, availability of adjunct surgery and whether treatment was provided free of charge for patients. The defi nition of treatment success utilised was considered appropriate if it was rated as similar to that recommended by the WHO: completion of treatment with at least fi ve negative cultures in the last 12 months of therapy or completion of therapy without evidence of treatment failure. 7 
Data analysis
We calculated point estimates and 95% confi dence intervals (CIs) for the proportion of patients achieving treatment success and the frequency of adverse events; our denominator included all patients who received linezolid irrespective of duration. The variance of the raw proportions was stabilised using a Freeman-Tukey type arcsine square-root transformation, 15 and estimates were pooled using a DerSimonian-Laird random effects model. 16 We calculated the τ 2 statistic to assess the proportion of overall variation attributable to between-study heterogeneity, as this is less affected by the number of studies than the more commonly used I 2 statistic. 17 Outcomes were stratifi ed according to dose of drug used and the potential effect of duration of treatment. The defi nition of treatment success was assessed in univariate sensitivity analyses. All P values are two-sided, and a P < 0.05 was considered signifi cant. Analyses were conducted using Stata (version 11, Stata Corp, College Station, TX, USA) and StatsDirect (version 2.5.2, StatsDirect Ltd, Cheshire, UK).
RESULTS
Our search strategy yielded 270 journal article abstracts, which ultimately yielded 49 full-text articles for review and 11 studies for fi nal inclusion ( Figure  1 ). The search of conference abstracts yielded fi ve abstracts, but none reported fi nal treatment outcomes. Of the full-text articles reviewed, two studies were excluded as they included patient data reported in subsequent studies. 18, 19 Study characteristics for the 11 included studies are summarised in Table 1 . [10] [11] [12] [20] [21] [22] [23] [24] [25] [26] [27] A total of 218 patients received linezolid, of whom 148 had evaluable outcomes; the remainder were reported to have been still receiving treatment at the time of publication. All patients were adults, and all were infected with MDR-TB, of whom at least 62 (28%) were infected with XDR-TB strains. Prior TB treatment with fi rst-and/or second-line treatment was variably reported, although several studies 12, 20, 21 reported median durations of prior treatment of years, compared to months, and previous second-line treatment was reported to have either failed or resulted in relapse for 50 patients. Indications for linezolid use included one or more of the following: failure of previous second-line treatment, use in 'salvage' regimens, the presence of extensive second-line drug resistance (variably defi ned, but including XDR-TB), or inability to tolerate other second-line medications. Concurrent HIV infection was reported for only eight patients (5% of total).
Linezolid dose varied considerably across studies, both at treatment initiation and after adjustment in the case of adverse events attributable to linezolid. The starting dose ranged between 300 and 1200 mg daily. The higher daily dose of 1200 mg was always delivered twice daily, whereas lower doses were given either singly or twice daily.
Overall, reporting of studies was generally poor. Only one study reported whether patients were hospitalised to receive linezolid treatment. 23 Three studies did not report treatment success according to the WHO defi nition, 20, 23, 26 and only two studies reported whether TB treatment including linezolid was provided free of charge 10, 12 (Table 2 ). However, although reporting was poor, the quality of treatment provided was judged to be good; all studies used individualised treatment regimens guided by DST, and higher generation fl uoroquinolones were reported to be available in over half of all studies. Table 2 shows the factors assessed as determinants of methodological quality.
Treatment success
Of the 148 patients with evaluable outcomes, 107 were successfully treated, giving an overall pooled proportion of treatment success of 67.99% (95%CI 58.00-78.99), with a moderate degree of heterogeneity, as expected for observational studies (τ 2 129.42; Figure 2 ). Among the 41 patients with poor outcomes, 18 died, treatment failed in 11, 10 defaulted and 2 were reported as a poor outcome without specifi cation. The total duration of linezolid treatment varied considerably both within and across studies, ranging from 1 week to 28 months (Table 1) .
In sensitivity analysis, the estimates of treatment success did not differ signifi cantly from the overall estimate if only studies using a defi nition of treatment success rated as similar to WHO recommendations were included (P = 0.81). The success of treatment did not differ in studies where linezolid was given for a mean duration of ⩽7 months (67.8%, 95%CI 58.0-78.0) compared to studies where linezolid was given for >7 months (66.9%, 95%CI 52.0-81.4, P = 0.92), and there was no signifi cant difference in the pooled estimates for treatment success between studies that used ⩽600 mg daily (66.9%, 95%CI 53.7-80.1) and studies that used >600 mg (61.6%, 95%CI 36.6-86.7, P = 0.7).
Culture conversion
Nine studies reported the proportion of patients who had converted sputum cultures from positive to negative during linezolid treatment: the pooled proportion was 97.86% (95%CI 95.19-100, τ 2 0). As the majority of these studies used doses of ⩽600 mg, a subgroup analysis by dose was not done.
Adverse events
All but one study reported overall rates of adverse events attributable to linezolid. Figure 3 ). The most commonly reported adverse events were neuropathies (peripheral and optic) and bone marrow suppression, particularly severe anaemia, often requiring transfusion. Pooled proportions of the frequency of neuropathy and bone marrow suppression were respectively 36.12% (95%CI 19.09-53.16) and 28.47% (95%CI 14.80-42.14; Figure 3) . The proportion of patients in whom linezolid was stopped due to adverse events ranged from 5.84% (95%CI 0.23-18.15) to 79.32% (95%CI 53.04-96.46) across nine studies, giving an overall pooled proportion of 36.23% (95%CI 20.67-51.79); the lowest rate was reported in the one study with a 
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5 starting dose of linezolid of 300 mg/day for the majority of patients. 21 One study did not describe adverse events attributable to linezolid, 25 and one study, although it reported signifi cant adverse events attributed to linezolid, did not state in how many patients treatment with linezolid was discontinued due to adverse events. 26 Overall, adverse events were the main reason for discontinuation of linezolid prior to treatment completion, although one study reported that treatment was discontinued after 3 months for some patients due to limited drug availability. 11 Eight studies reported adverse events according to the dose of linezolid. A sensitivity analysis of the frequency of adverse events among patients receiving a linezolid dose of ⩽600 mg daily compared to those receiving >600 mg daily suggests a trend towards a lower frequency of adverse events among patients receiving lower doses: 34.40% (95%CI 23.02-45.77) for ⩽600 mg vs. 49.85% (37.31-62.38) for >600 mg (P = 0.07). The proportion of adverse events necessitating treatment discontinuation was signifi cantly different by dose: 29.49% (95%CI 3.24-55.74) for 6 The International Journal of Tuberculosis and Lung Disease ⩽600 mg vs. 60.75% (95%CI 42.69-78.81) for >600 mg (P = 0.05).
DISCUSSION
The poor safety profi le associated with long-term use of linezolid and the lack of evidence of clinical efficacy has led linezolid to be used primarily for patients considered to have 'intractable' or 'complicated' DR-TB, including those in whom treatment using recommended second-line drugs has failed or those with XDR-TB, with susceptibility to few available drugs. This systematic review and meta-analysis has shown a high proportion of treatment success when linezolid is used to treat these complicated MDR-TB patients.
Our pooled proportion of 68% treatment success is in line with outcomes for MDR-TB treatment in general: two recent meta-analyses both reported a pooled proportion of 62% treatment success for patients with uncomplicated MDR-TB. 2, 4 As linezolid has been used as part of a multidrug regimen in the studies included in this review, this level of treatment success may not be solely attributed to linezolid use. A number of included studies also used higher generation fl uoroquinolones that have been shown to be effi cacious in DR-TB treatment, particularly for XDR-TB. 3, 6 Determining the independent contribution of linezolid is therefore problematic, as is the case for any drug used for DR-TB treatment. However, in the majority of included studies, few drugs with demonstrated susceptibility were able to be included in treatment regimens, and this patient group has been shown to have particularly poor outcomes: 44% treatment success for XDR-TB 3 and similar or lower for MDR-TB cases previously treated with second-line drugs. 28, 29 The data thus suggest a signifi cant benefi t from the inclusion of linezolid in the treatment regimen.
The high frequency of adverse events is an important limitation of linezolid. Severe adverse events -predominantly neuropathies and bone marrow suppression-lead to discontinuation of linezolid in over a third of patients and dose reduction in others. Although our analysis was limited by the small number of studies resulting in a low overall sample size, our results indicate that a reduced daily dose of ⩽600 mg from treatment initiation may lower the frequency of occurrence of adverse events without impacting treatment success. In particular, reducing the daily dose may reduce the impact of bone marrow suppression, particularly severe anaemia, as has been suggested previously. 12 Linezolid has been approved for use at 800-1200 mg daily for the short-term treatment of bacterial infections, and due to the relatively short half-life of 5-7 h, 12-h dosing is recommended. 30 However, there are limited data for linezolid with regard to Mycobacterium tuberculosis, and lower doses, potentially given once daily for longer periods, may be suffi cient against TB, particularly when used in combination as multidrug regimens.
Notably, a relatively high treatment success was demonstrated in these studies, although high proportions of patients required linezolid to be discontinued early, with no signifi cant difference in treatment success between studies in which linezolid was given for a mean duration of less than 7 months compared to longer. However, the high initial culture conversion compared to lower overall treatment success suggests that stopping treatment early may have consequences on long-term outcome. This discrepancy highlights the need for pharmacokinetic and randomised trial data to optimise dosing and duration, not only for initial culture conversion but also for fi nal treatment outcomes.
Our systematic review is subject to several limitations. First, reporting of included patients and outcomes was not consistent across studies, and the outcome of treatment success was often not reported by important variables such as linezolid dose and duration. Second, criteria for reporting adverse events were invariably not reported, and interpretation of adverse event rates should therefore be made with caution. Third, as with any systematic review, limitations associated with potential publication bias should be considered. Statistical methods are not appropriate for the formal assessment of publication bias, but we acknowledge the risk of such bias. 31 Fourth, a proportion of patients included in the studies did not have treatment outcomes reported, the majority of whom were still receiving treatment at the time of publication. Although these patients could be still receiving treatment while remaining culture-positive (potential treatment failure), given the high level of culture conversion reported, it is more likely that these are patients who have culture-converted and are still to complete their treatment (potential treatment success). Finally, our overall sample size was small and all data were observational, resulting in low statistical precision and a moderate degree of heterogeneity. We used a random-effects model which is more appropriate for meta-analyses in which heterogeneity is anticipated, and explored potential sources of heterogeneity in a series of subgroup analyses. The fact that point estimates for treatment success were relatively consistent across studies lends further confi dence to the pooled estimates.
Overall, the available data suggest that linezolid is a potentially useful drug in treating the signifi cant proportion of MDR-TB patients in whom secondline regimens fail or who are infected with TB strains with such signifi cant resistance as not to allow the formulation of an appropriate second-line regimen using recommended drugs. However, the high frequency of serious adverse events suggests that linezolid should be used with some caution, in settings where adverse events can be monitored and patients hospitalised if needed. Some adverse events, such as optic or peripheral neuropathy, may be irreversible and debilitating. This risk needs to be balanced against the paucity of effective treatment options for patients with DR-TB and the possibility of cure afforded by the use of linezolid, as has been done for other MDR-TB drugs with important side effects, such as kanamycin and amikacin, which are associated with signifi cant and often irreversible hearing loss in more than a third of patients. 32 Adverse events are not the only barriers to linezolid use for DR-TB treatment. In South Africa, where linezolid is patent protected, linezolid costs approximately US$2500 per month of treatment (at 600 mg daily). In contrast, in India, where linezolid is not patented, generic production has reduced the cost to between US$50-70/month. In addition to lower cost, the quality of linezolid preparations, and particularly nonvalidated generic forms, needs to be assured before more widespread use. While some progress has been made in the development of new drugs for MDR-TB, the urgent need for better treatment regimens requires that the use of existing drugs should also be pursued more thoroughly. 33 Encouragingly, at least two randomised controlled trials are underway to assess the use of linezolid in DR-TB treatment. Preliminary results are promising, with high levels of culture conversion but as yet no published treatment outcomes. 34, 35 Furthermore, a new oxazolidinone 100480 (PNU-100480) has been shown to have improved anti-tuberculosis activity 36 and is currently in Phase 1 trials for TB. The urgent need to scale up treatment for DR-TB highlights the defi ciencies in currently available second-line treatment regimens for TB and underlines the urgent need to develop new drugs and use those already available, such as linezolid, more effectively.
